EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 29 / Numéro 5 (Mai 2013) Med Sci (Paris), 29 5 (2013) 523-528 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 29, Numéro 5, Mai 2013
Page(s) 523 - 528
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2013295016
Publié en ligne 28 mai 2013
  1. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964 ; 86 : 1646–1647. [CrossRef] [Google Scholar]
  2. Scotter EL, Abood ME, Glass M. The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharm 2010 ; 160 : 480–498. [CrossRef] [Google Scholar]
  3. Fogli S, Breschi MC. The molecular bases of cannabinoid action in cancer. Cancer Therapy 2008 ; 6 : 103–116. [Google Scholar]
  4. MacCoun R, Reuter P. Evaluating alternative cannabis regimes. Br J Psychiatry 2001 ; 178 : 123–128. [CrossRef] [PubMed] [Google Scholar]
  5. Hazekamp A, Grotenhermen F. Review on clinical studies with cannabis and cannabinoids 2005–2009. cannabinoids 2010 ; 5 : 1–21. [Google Scholar]
  6. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003 ; 4 : 873–884. [CrossRef] [PubMed] [Google Scholar]
  7. Giuffrida R, Beltramo M, Piomelli D. Mechanism of endocannabinoid inactivation: biochemistry and pharmacology. J Pharm Exp Ther 2001 ; 298 : 7–14. [Google Scholar]
  8. Steffens S, Mach M. Vers un usage thérapeutique de ligands sélectifs du récepteur cannabinoïde 2 dans l’athérosclérose. Med Sci (Paris) 2006 ; 1 : 7–9. [CrossRef] [EDP Sciences] [Google Scholar]
  9. Vandevoorde S, Lambert DM. Focus on the three key enzymes hydrolysing endocannabinoids as new drug targets. Curr Pharm Des 2005 ; 18 : 2647–2668. [CrossRef] [Google Scholar]
  10. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev 2008 ; 7 : 438–455. [CrossRef] [Google Scholar]
  11. Munro LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990 ; 346 : 561–564. [CrossRef] [PubMed] [Google Scholar]
  12. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993 ; 365 : 61–65. [CrossRef] [PubMed] [Google Scholar]
  13. Onaivi ES. An endocannabinoid hypothesis of drug reward and drug addiction. Ann N Y Acad Sci 2008 ; 1139 : 412–421. [CrossRef] [PubMed] [Google Scholar]
  14. Galiègue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995 ; 232 : 54–61. [CrossRef] [PubMed] [Google Scholar]
  15. Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005 ; 310 : 329–332. [CrossRef] [PubMed] [Google Scholar]
  16. Yang P, Wang L, Xie X-Q. Latest advances in novel cannabinoid CB2 ligands for drug abuse and their therapeutic potential. Future Med Chem 2012 ; 4 : 187–204. [CrossRef] [PubMed] [Google Scholar]
  17. Sharir H, Console-Bram L, Mundy C, et al. The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55. J Neuroimmune Pharmacol 2012 ; 7 : 56–65. [CrossRef] [Google Scholar]
  18. Di Marzo V, De Petrocellis L. Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs. Curr Med Chem 2010 ; 17 : 1430–49. [CrossRef] [PubMed] [Google Scholar]
  19. Klegeris A, Bissonnette CJ, McGeer PL. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol 2003 ; 139 : 775–786. [CrossRef] [PubMed] [Google Scholar]
  20. Venance L, Maldonado R. Manzoni. Le système endocannabinoïde central. Med Sci Paris 2004 ; 1 : 45–53. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  21. Pacher P, Mechoulam R. Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 2011 ; 50 : 193–211. [CrossRef] [PubMed] [Google Scholar]
  22. Wright K, Rooney N, Feeney M, et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 2005 ; 129 : 437–453. [PubMed] [Google Scholar]
  23. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002 ; 347 : 417–429. [CrossRef] [PubMed] [Google Scholar]
  24. Di Marzo V, Izzo AA. Endocannabinoid overactivity and intestinal inflammation. Gut 2006 ; 55 : 1373–1376. [CrossRef] [PubMed] [Google Scholar]
  25. Ihenetu K, Molleman A, Parsons ME, et al. Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids. Eur J Pharmacol 2003 ; 458 : 207–215. [CrossRef] [PubMed] [Google Scholar]
  26. Kunos G, Pacher P. Cannabinoids cool the intestine. Nat Med 2004 ; 10 : 678–679. [CrossRef] [PubMed] [Google Scholar]
  27. Ehrhart J, Obregon D, Mori T, et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflam 2005 ; 2 : 29. [CrossRef] [Google Scholar]
  28. Leleu-Chavain N, Body-Malapel M, Spencer J, et al. Recent advances in the development of selective CB2 agonists as promising anti-inflammatory agents. Curr Med Chem 2012 ; 19 : 3457–3474. [CrossRef] [PubMed] [Google Scholar]
  29. Calignano A, La Rana G, Giuffrida A, et al. Control of pain initiation by endogenous cannabinoids. Nature 1998 ; 394 : 277–281. [CrossRef] [PubMed] [Google Scholar]
  30. Guindon J, Beaulieu P. Antihyperlagesic effects of local injections of anandamide, ibuprofenn rofecoxib and their combinations in a model of neuropathic pain. Neuropharmacology 2006 ; 50 : 814–823. [CrossRef] [PubMed] [Google Scholar]
  31. Kikuchi A, Ohashi K, Sugie Y, et al. Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity. J Pharmacol Sci 2008 ; 106 : 219–224. [CrossRef] [PubMed] [Google Scholar]
  32. Lucas P. Cannabis as an adjunct to or substitute for opiates in the treatment of chronic pain. J Psychoactive Drugs 2012 ; 44 : 125–133. [CrossRef] [PubMed] [Google Scholar]
  33. Calvino B. Les kératinocytes : des cellules non neuronales impliquées dans la douleur. Douleurs Évaluation - Diagnostic - Traitement 2010 ; 11 : 120–130. [CrossRef] [Google Scholar]
  34. Sarfaraz S, Afaq F, Adhami VM, et al. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res 2005 ; 65 : 1635–1641. [CrossRef] [PubMed] [Google Scholar]
  35. Blazquez C, Casanova ML, Planas A, et al. Inhibition of tumor angiogenesis by cannabinoids. FASEB J 2003 ; 17 : 529–531. [PubMed] [Google Scholar]
  36. Fatima Teixeira-Clerc, Boris Julien, Pascale Grenard, et al. Les antagonistes du récepteur CB1 des cannabinoïdes : une nouvelle approche pour le traitement de la fibrose hépatique. Med Sci (Paris) 2006 ; 22 : 683–685. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.